|
1
|
Liu Y: Cellular and molecular mechanisms
of renal fibrosis. Nat Rev Nephrol. 7:684–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu X and Dai C: Advances in understanding
and management of residual renal function in patients with chronic
kidney disease. Kidney Dis (Basel). 2:187–196. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bianco P, Cao X, Frenette PS, Mao JJ,
Robey PG, Simmons PJ and Wang CY: The meaning, the sense and the
significance: Translating the science of mesenchymal stem cells
into medicine. Nat Med. 19:35–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Monsel A, Zhu YG, Gennai S, Hao Q, Liu J
and Lee JW: Cell-based therapy for acute organ injury: Preclinical
evidence and ongoing clinical trials using mesenchymal stem cells.
Anesthesiology. 121:1099–1121. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gnecchi M, Zhang Z, Ni A and Dzau VJ:
Paracrine mechanisms in adult stem cell signaling and therapy. Circ
Res. 103:1204–1219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duffield JS and Bonventre JV: Kidney
tubular epithelium is restored without replacement with bone
marrow-derived cells during repair after ischemic injury. Kidney
Int. 68:1956–1961. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jeong JO, Han JW, Kim JM, Cho HJ, Park C,
Lee N, Kim DW and Yoon YS: Malignant tumor formation after
transplantation of short-term cultured bone marrow mesenchymal stem
cells in experimental myocardial infarction and diabetic
neuropathy. Circ Res. 108:1340–1347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kunter U, Rong S, Boor P, Eitner F,
Müller-Newen G, Djuric Z, van Roeyen CR, Konieczny A, Ostendorf T,
Villa L, et al: Mesenchymal stem cells prevent progressive
experimental renal failure but maldifferentiate into glomerular
adipocytes. J Am Soc Nephrol. 18:1754–1764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
da Silva AF, Silva K, Reis LA, Teixeira VP
and Schor N: Bone Marrow-derived mesenchymal stem cells and their
conditioned medium attenuate fibrosis in an irreversible model of
unilateral ureteral obstruction. Cell Transplant. 24:2657–2666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Koppen A, Joles JA, van Balkom BW, Lim
SK, de Kleijn D, Giles RH and Verhaar MC: Human embryonic
mesenchymal stem cell-derived conditioned medium rescues kidney
function in rats with established chronic kidney disease. PLoS One.
7:e387462012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang B, Cheng X, Wang H, Huang W, la Ga
Hu Z, Wang D, Zhang K, Zhang H, Xue Z, Da Y, et al: Mesenchymal
stem cells and their secreted molecules predominantly ameliorate
fulminant hepatic failure and chronic liver fibrosis in mice
respectively. J Transl Med. 14:452016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohnishi S, Sumiyoshi H, Kitamura S and
Nagaya N: Mesenchymal stem cells attenuate cardiac fibroblast
proliferation and collagen synthesis through paracrine actions.
FEBS Lett. 581:3961–3966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han H, Zhu J, Wang Y, Zhu Z, Chen Y, Lu L,
Jin W, Yan X and Zhang R: Renal recruitment of B lymphocytes
exacerbates tubulointerstitial fibrosis by promoting monocyte
mobilization and infiltration after unilateral ureteral
obstruction. J Pathol. 241:80–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aslam M, Baveja R, Liang OD,
Fernandez-Gonzalez A, Lee C, Mitsialis SA and Kourembanas S: Bone
marrow stromal cells attenuate lung injury in a murine model of
neonatal chronic lung disease. Am J Respir Crit Care Med.
180:1122–1130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nilsson L, Madsen K, Krag S, Frøkiær J,
Jensen BL and Nørregaard R: Disruption of cyclooxygenase type 2
exacerbates apoptosis and renal damage during obstructive
nephropathy. Am J Physiol Renal Physiol. 309:F1035–F1048. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kay AG, Long G, Tyler G, Stefan A,
Broadfoot SJ, Piccinini AM, Middleton J and Kehoe O: Mesenchymal
stem cell-conditioned medium reduces disease severity and immune
responses in inflammatory arthritis. Sci Rep. 7:180192017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ooi YY, Dheen ST and Tay SS: Paracrine
effects of mesenchymal stem cells-conditioned medium on microglial
cytokines expression and nitric oxide production.
Neuroimmunomodulation. 22:233–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao F, Wang Y, Li S, Wang Z, Liu C and Sun
D: Inhibition of p38 mitogen-activated protein kinases attenuates
renal interstitial fibrosis in a murine unilateral ureteral
occlusion model. Life Sci. 167:78–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watatani H, Maeshima Y, Hinamoto N,
Yamasaki H, Ujike H, Tanabe K, Sugiyama H, Otsuka F, Sato Y and
Makino H: Vasohibin-1 deficiency enhances renal fibrosis and
inflammation after unilateral ureteral obstruction. Physiol Rep.
2:pii: e12054. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma W, Tao L, Wang X, Liu Q, Zhang W, Li Q,
He C, Xue D, Zhang J and Liu C: Sorafenib inhibits renal fibrosis
induced by unilateral ureteral obstruction via inhibition of
macrophage infiltration. Cell Physiol Biochem. 39:1837–1849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bohle A, Wehrmann M, Bogenschütz O, Batz
C, Vogl W, Schmitt H, Müller CA and Müller GA: The long-term
prognosis of the primary glomerulonephritides. A morphological and
clinical analysis of 1747 cases. Pathol Res Pract. 188:908–924.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eardley Sean K and Cockwell P: Macrophages
and progressive tubulointerstitial disease. Kidney Int. 68:437–455.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wynn TA, Chawla A and Pollard JW:
Macrophage biology in development, homeostasis and disease. Nature.
496:445–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chevalier RL, Forbes MS and Thornhill BA:
Ureteral obstruction as a model of renal interstitial fibrosis and
obstructive nephropathy. Kidney Int. 75:1145–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tesch GH: MCP-1/CCL2: A new diagnostic
marker and therapeutic target for progressive renal injury in
diabetic nephropathy. Am J Physiol Renal Physiol. 294:F697–F701.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haller H, Bertram A, Nadrowitz F and Menne
J: Monocyte chemoattractant protein-1 and the kidney. Curr Opin
Nephrol Hypertens. 25:42–49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O'Connor T, Borsig L and Heikenwalder M:
CCL2-CCR2 signaling in disease pathogenesis. Endocr Metab Immune
Disord Drug Targets. 15:105–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
